-+ 0.00%
-+ 0.00%
-+ 0.00%

Conexeu Sciences Names Daniel M. Bradbury Board Chairman, Effective Dec. 1

PUBT·11/19/2026 13:32:29
Listen to the news
Conexeu Sciences Names Daniel M. Bradbury Board Chairman, Effective Dec. 1
  • Conexeu Sciences appointed Daniel M. Bradbury board chairman, effective December 1, 2026, succeeding Jeff Sharpe, who stepped down as chairman and director.
  • Bradbury served as Amylin Pharmaceuticals’ president and CEO from March 2007 until its acquisition by Bristol-Myers Squibb in August 2012.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190830PRIMZONEFULLFEED9881083) on November 19, 2026, and is solely responsible for the information contained therein.